Caption Management, LLC Sage Therapeutics, Inc. Call Options Transaction History

Caption Management, LLC

$6.13 Billion
Q2 2024

Call Options

15 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q2 2024 Aug 14, 2024	SELL	$10.58 - $17.9 $230,644 - $390,219	-21,800 Reduced 72.67%	8,200 $89,000
Q4 2023 Feb 14, 2024	SELL	$17.1 - $22.26 $513,000 - $667,800	-30,000 Reduced 50.0%	30,000 $650,000
Q3 2023 Nov 14, 2023	BUY	$16.75 - $48.98 $502,500 - $1.47 Million	30,000 Added 100.0%	60,000 $1.23 Million
Q1 2023 May 15, 2023	BUY	$37.27 - $46.57 $1.12 Million - $1.4 Million	30,000 New	30,000 $1.26 Million
Q1 2022 May 13, 2022	SELL	$30.71 - $45.71 $7.88 Million - $11.7 Million	-256,600 Reduced 99.46%	1,400 $47,000
Q4 2021 Feb 11, 2022	BUY	$37.06 - $47.11 $8.45 Million - $10.7 Million	228,000 Added 760.0%	258,000 $11 Million
Q3 2021 Nov 12, 2021	BUY	$40.26 - $57.37 $100,650 - $143,425	2,500 Added 9.09%	30,000 $1.33 Million
Q2 2021 Aug 16, 2021	SELL	$54.88 - $79.29 $208,544 - $301,302	-3,800 Reduced 12.14%	27,500 $1.56 Million
Q1 2021 May 17, 2021	BUY	$70.65 - $96.76 $2.21 Million - $3.03 Million	31,300 New	31,300 $2.34 Million
Q2 2020 Aug 14, 2020	SELL	$25.95 - $43.15 $519,000 - $863,000	-20,000 Closed	0 $0
Q1 2020 May 15, 2020	SELL	$26.15 - $77.24 $985,855 - $2.91 Million	-37,700 Reduced 65.34%	20,000 $574,000
Q4 2019 Feb 13, 2020	SELL	$60.18 - $154.77 $288,864 - $742,896	-4,800 Reduced 7.68%	57,700 $4.16 Million
Q3 2019 Nov 14, 2019	BUY	$140.29 - $189.96 $4.55 Million - $6.15 Million	32,400 Added 107.64%	62,500 $8.77 Million
Q2 2019 Aug 13, 2019	BUY	$157.85 - $183.09 $1.59 Million - $1.85 Million	10,100 Added 50.5%	30,100 $5.51 Million
Q4 2018 Jan 30, 2019	BUY	$81.94 - $139.71 $1.64 Million - $2.79 Million	20,000 New	20,000 $1.92 Million

Others Institutions Holding SAGE

# of Institutions

218

Shares Held

46.4M

Call Options Held

847K

Put Options Held

188K

View Full List

About Sage Therapeutics, Inc.

Ticker SAGE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,422,300
Market Cap $340M
Description
Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive...

More about SAGE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Caption Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Caption Management, LLC with notifications on news.

Account